FDA cleared a record-breaking 106 medical devices in 2018

It was a record-breaking year for medical device approvals in the FDA, with the government agency approving 106 novel devices in 2018—beating out 2017’s 99 novel device approvals.

The FDA also cleared nine breakthrough devices in 2018, including AI technologies that detect wrist fractures and diabetic retinopathy. Late last year, the agency granted breakthrough device designation to new software being jointly developed by Bayer and Merck that uses AI to diagnose chronic thromboembolic pulmonary hypertension (CTEPH).

“Our effort to promote innovation is eclipsed only by our commitment to make sure that these products are safe for patients,” FDA Commissioner Scott Gottlieb, MD, and Jeff Shuren, MD, director of the Center for Devices and Radiological Health, wrote in a statement. “Our success in providing patients with new treatments and diagnostics, and more options for effective healthcare, are not coming at the expense of the robust non-clinical and clinical science on which we rely to make our regulatory decisions.”

For 2019, the FDA said it plans to focus on both device safety and innovation. The agency's year will include moving forward with plans to implement the National Evaluation System for Health Technology (NEST), establish safety and performance criteria for certain types of devices and issue a proposed framework for the Safer Technologies Program (STeP).

“Our success in driving better safety and greater innovation depends, in part, on our ability to be innovative. We need to be able to continually adapt our frameworks, try new approaches and, where necessary, seek new authorities because science does not stand still,” Gottlieb and Shuren wrote. "Not only must we keep pace with this complexity and innovation, but we must also stay ahead of the new and evolving risks that can sometimes accompany novel products.”

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”